Janssen seeks US FDA nod to market simeprevir in HCV
This article was originally published in Scrip
Executive Summary
Janssen Research & Development, part of Johnson & Johnson, is seeking the US FDA's approval to market simeprevir (TMC435), an investigational once-daily NS3/4A protease inhibitor, administered with pegylated interferon and ribavirin, to treat genotype 1 chronic hepatitis C virus (HCV) in adults.